135 related articles for article (PubMed ID: 992711)
1. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
2. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
3. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
4. The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.
Amos N; Sissons JG; Girard JF; Lachmann PJ; Peters DK
Clin Exp Immunol; 1976 Jun; 24(3):474-82. PubMed ID: 939051
[TBL] [Abstract][Full Text] [Related]
5. Initiation of C3 cleavage in the alternative complement pathway.
Fearon DT; Austen KF
J Immunol; 1975 Nov; 115(5):1357-61. PubMed ID: 809512
[TBL] [Abstract][Full Text] [Related]
6. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
7. Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF).
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Feb; 116(2):568-70. PubMed ID: 1249423
[No Abstract] [Full Text] [Related]
8. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function.
Daha MR; Austen KF; Fearon DT
J Immunol; 1977 Sep; 119(3):812-7. PubMed ID: 894027
[No Abstract] [Full Text] [Related]
9. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
10. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
11. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
12. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
13. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
Daha MR; van Es LA
J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
[TBL] [Abstract][Full Text] [Related]
14. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
15. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
Baker PJ; Adler S; Yang Y; Couser WG
J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
[TBL] [Abstract][Full Text] [Related]
16. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
Daha MR; van Es LA
J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
[TBL] [Abstract][Full Text] [Related]
17. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
Arnaout MA; Davis AE; Rosen RS; Alper CA
J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
[TBL] [Abstract][Full Text] [Related]
18. Interaction of C3b, B, and D in the alternative pathway of complement activation.
Nicholson A; Brade V; Schorlemmer HU; Burger R; Bitter-Suermann D; Hadding U
J Immunol; 1975 Oct; 115(4):1108-13. PubMed ID: 240884
[TBL] [Abstract][Full Text] [Related]
19. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
20. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]